Thank you, Andreas. So, the addressable market for Orviglance has a global value of $800 million annually. The US represents almost half of this. This market opportunity for Orviglance addresses the unmet need for a well-defined patient population. Cancer patients who need liver imaging and who also have severely impaired kidney function. Our strategy for commercialization is to launch through partners. This strategy supports our ambition to secure the optimal balance between future revenues and investment required. And it allows us to leverage commercial capabilities already established by a partner. Our focused, ambitious loan strategy and plans build on advanced market insights, and these are in place to support this partnering strategy and to support the launch. As mentioned, the US is the largest commercial opportunity in the US alone. Our real world data, i.e. data from realized procedures in our target patient population, show that every year a hundred thousand abdominal imaging procedures are performed in 50,000 patients that fall under the black box warning. For gadolinium contrast agents, this is about 4% of cancer patients that undergo abdominal imaging. The well-defined patient population with a clear unmet need also drives an attractive pricing opportunity. And we have extensive input from market access and pricing experts, with whom we tested different price levels and collected insights on the evidence needed to support access and reimbursement at launch. And we have also investigated pricing and access benchmarks for other innovative diagnostic drugs in the US. 90% of health care professionals are concerned with the issues related to gadolinium contrast agents, including nephrogenic systemic fibrosis, or NSF, as Andrea has mentioned. In fact, 16% of providers have experienced gadolinium-induced NSF. These insights come from market research, with 270 US healthcare professionals and answers from radiologists, nephrologists, and oncologists. And these insights confirm the concerns with gadolinium in clinical practice and the unmet need for Orviglance. When speaking to experts, whether in radiology or nephrology. They also confirm that an alternative to gadolinium for our target patient population would address concerns of today. Supporting the potential for Orviglance to become a valuable addition to clinical practice. In clinical practice, the unmet need for our target patient population is also well recognized. Physicians tell us that patients who need liver imaging and fall under the black box warning for gadolinium today receive MRIs that balance the trade-off between, on the one hand, being without a contrast agent, i.e. an inferior image quality, or by being a half dose scheduled in them. These are around 80% of the patients in total. Or by being with a full gadolinium dose, with the awareness that gadolinium is not recommended for these patients due to the black box warning. All of these patients are potential Orviglance patients. Beyond the risk of NSF in kidney impaired patients, gadolinium is well known to be retained in the brain and other tissues in all patients. And scrutiny over the possible safety effects is a key concern of regulators and medical bodies. It is also well known that gadolinium is excreted via the kidneys in urine, because it's difficult to remove in our sewage systems. This is discharged into the environment, even into our drinking water. So there is an urgency from regulators and medical bodies to find a viable alternative to the growing use of toxic gadolinium. And the answer to that is not associated with these potential safety and environmental concerns for patients and the environment with gadolinium. So, in short, the momentum for an alternative to gadolinium is getting better and better, and the industry is responding to this. Recent developments from large gadolinium manufacturers are focused on smaller doses of gadolinium, and thus even an early stage injectable manganese based contrast agent, which is not like, um. Not like all the claims because it's not liver specific. So we are excited that we have a head start, and that the upcoming weekend is expected to be a first in class to lead a future with less gadolinium and improved outcomes for our target patients. The go-to-market strategy for all the drugs is to launch with commercialization partners. This supports our objectives to secure the optimal balance between future revenues and investment required. And as mentioned, it also allows us to leverage the commercial capabilities already established by our partner. So the focus of Ascelia is to continue the dialogue with potential partners, and to ensure that all clients and their partners are ready to launch upon approval. So we are both excited and optimistic. About our launch preparations and our partnering opportunities. And also because almost all physicians tell us that they would like to use our exams when they are available on the market. So in summary, our drug addresses a well-defined unmet need and it represents an attractive commercial opportunity. Our focus is to ensure that our drug is ready for launch with a partner. And all our efforts to help patients and to launch the drug are well recognized by experts and partners in the industry. With this, I will hand over to Andreas Norlin to talk about Oncoral.